Single-Agent Drug Proves Effective in Previously-Treated Marginal Zone Lymphoma


A single-agent therapy is an effective chemotherapy-free option for patients with marginal zone lymphoma previously exposed to conventional monotherapy, according to a study presented recently at the American Society of Hematology Annual Meeting and Exposition (December 8-12, 2017; Atlanta, GA).

The study reported additional analyses from a phase 2 study of patients with relapsed/refractory marginal zone lymphoma whose prior treatment included one or more CD20-containing regimens. Sixty-three enrolled patients received oral ibrutinib (560 mg once daily) for up to 3 years or until disease progression or unacceptable toxicity.

Single-agent ibrutinib showed a trend toward higher overall response rate and median progression-free survival, as well as a quicker response, in patients with relapsed/refractory marginal zone lymphoma who had previously received rituximab monotherapy compared with patients who received rituximab-based chemoimmunotherapy, researchers reported.

The overall response rate for patients who had received rituximab only was 69% compared with 46% for patients who had received rituximab-based chemoimmunotherapy. The estimated 18-month progression-free survival rate was 68% for patients who had received prior rituximab monotherapy and 35% for those who had received prior rituximab-based chemoimmunotherapy, according to the study.

“In all cases,” researchers wrote, “continued treatment with ibrutinib resulted in increased clinical benefit.”


Related Content

Novel Prognostic Index Designed for Patients With MZL

Clinical Pathways, Targeted Therapies Likely to Shape Future MZL Treatment


Additionally, researchers reported that MYD88 and TNFAIP3 mutations in the BCR-NFkB signaling pathway were positively linked with patient response. However, mutations in NOTCH2 and KMT2D, which are not involved in BCR-NFkB signaling, were negatively associated with patient response. —Jolynn Tumolo